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Background: Serine proteinase inhibitors (serpins) finely regulate serine proteinase activity via a suicide substrate-like
inhibitory mechanism. In parasitic nematodes, some serpins interact with host physiological processes; however, little is
known about these essential molecules in Anisakis. This article reports the gene sequencing, cloning, expression and
preliminary biochemical and bioinformatically-based structural characterization of a new Anisakis serpin (ANISERP).
Methods: The full AniSerp gene was cloned by specific RACE-PCR after screening an Anisakis simplex (L3) cDNA library.
For biochemical assays, the AniSerp gene was subcloned into both prokaryotic and eukaryotic vectors, and the
recombinant proteins were purified. The inhibitory properties of the proteins were tested in classical biochemical assays
using human serine peptidases and AMC substrates. Immunolocalization of ANISERP, theoretical structural analysis and
bioinformatically-based structural modelling of the ANISERP protein were also conducted.
Results: The AniSerp gene was found to have 1194 nucleotides, coding for a protein of 397 amino acid residues plus a
putative N-terminal signal peptide. It showed significant similarity to other nematode, arthropod and mammalian
serpins. The recombinant ANISERP expressed in the prokaryotic and eukaryotic systems inhibited the human
serine proteases thrombin, trypsin and cathepsin G in a concentration-dependent manner. No inhibitory activity
against Factor Xa, Factor XIa, Factor XIIa, elastase, plasmin or chymotrypsin was observed. ANISERP also acted on
the cysteine protease cathepsin L. ANISERP was mainly localized in the nematode pseudocoelomic fluid, somatic
muscle cell bodies and intestinal cells. The findings of molecular dynamics studies suggest that ANISERP inhibits
thrombin via a suicide substrate-like inhibitory mechanism, similar to the mechanism of action of mammalian
coagulation inhibitors. In contrast to findings concerning human antithrombin III, heparin had no effect on ANISERP
anticoagulant inhibitory activity.
Conclusions: Our findings suggest that ANISERP is an internal Anisakis regulatory serpin and that the inhibitory activity
against thrombin depends on a suicide substrate-like inhibitory mechanism, similar to that described for human
antithrombin (AT)-III. The fact that heparin does not modulate the anticoagulant activity of ANISERP might be
explained by the absence in the latter of five of the six positively charged residues usually seen at the AT-III-heparin
binding site.
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Anisakis spp. are parasitic nematodes that infect the
gastrointestinal tract of sea mammals [1], producing gastric
ulcers and haemorrhagic exudates; they can also penetrate
the abdominal cavity by crossing the gastrointestinal
wall [2]. Humans are accidental hosts that become affected
via the ingestion of Anisakis larvae present in raw or
undercooked fish and seafood. Human Anisakis infec-
tion causes gastrointestinal disease with mild to severe
clinical symptoms such as nausea, vomiting, diarrhoea,
and abdominal and epigastric pain [3]. Occult blood is
often present in the gastric juice and faeces [4]. Gastro-
intestinal symptoms are often associated with allergic
reactions involving specific IgE responses to parasite
allergens [5–7].
The serpins belong to the superfamily of serine peptidase
inhibitors and are expressed by many organisms ranging
from plants to vertebrates. They help to control proteolysis
in molecular pathways associated with tissue homeostasis/
cell survival, development, and host defence [8]. Some
have cross-class activity and can inhibit cysteine proteinases
[9, 10]; others may even behave as non-inhibitory chaper-
ones, tumour suppressors or transport molecules [8].
Serpin expression in parasites, especially helminths, is
the subject of intense study [11–13]. In nematodes, serpins
interact with endogenous parasite proteinases and some are
also believed to play important roles in defence against
digestion by host proteinases, inhibition of the host im-
mune response, and even as immunomodulators [12, 14].
In Anisakis, only four serine proteinase inhibitors have
been characterized to date: Anisakis ASP1, ASP2 and
Ani s 6, which belong to a unique class of nematode in-
hibitors (smapins), and Ani s 1, an allergen belonging to
the Kunitz-type family [15–18]. The present article re-
ports the molecular and biochemical characterization of
ANISERP, a new Anisakis serpin [GenBank™: FR694897].
Methods
AniSerp gene cloning
An Anisakis simplex truncated cDNA that showed notable
similarity to serpin genes (NCBI) was obtained by screen-
ing a cDNA library obtained from the L3 stage larvae.
Amplification of the 5′ end was performed by RACE-PCR
and using a parasite cDNA collection prepared with the
Marathon cDNA amplification kit (Clontech) and the
forward primer AP1 (5′ CTAATACGACTCACTATAG
GGC 3′), which corresponds to the AP1 adaptor sequence
of the A.simplex cDNA collection, and reverse primer SR1
(5′ ACCCGCAGTAGTTTTATCCATTTGTTCG 3′), the
design of which was based on the truncated cDNA
sequence. On the basis of the information obtained, two
new primers were used to amplify the full gene by PCR: the
forward primer SER5′ (5′ ATGATGACAGCATTACCGT
TTTTAAC 3′) and the reverse primer SER3′ (5′ TCAGTGGAAACGACCAATAAACAGAATGCG 3′). The gene
was named AniSerp. Standard amplification protocols were
used in all cases [19].
Bioinformatic analysis
The theoretical molecular weight and isoelectric point of
the full ANISERP protein were obtained using the
Expasy Compute pI/Mw tool (http://web.expasy.org/
compute_pi/). The protein sequence was also compared
with sequences included in the GenBank database, by
using the BLASTp program [20], and its motifs were
characterised using ScanProsite software (ExPASY
Bioinformatics Resource Server; http://www.expasy.org/
proteomics). The putative N-terminal signal peptide in
the protein was predicted using the SignalP 4.1 Server
program [21].
Subcloning, expression in Escherichia coli and purification
of recombinant ANISERP protein
The AniSerp gene without the sequence coding for the
predicted putative N-terminal signal peptide was sub-
cloned into the pGEX4T2 expression vector (GE Health-
care Life Sciences) and further transformed into the
BL21 strain of E. coli (F-, ompT, hsdS [rb-, mb-], gal)
(GE Healthcare Life Sciences). Recombinant protein ex-
pression was induced by different protocols to obtain a
soluble fusion protein similar to the native protein,
which was subsequently purified. Expression protocols
including different combinations of incubation tempera-
tures (16 and 37 °C), concentrations of isopropyl β-D-1-
thiogalactopyranoside (ITPG) (0.01, 0.1, 0.5 and 1 mM)
and incubation times (4-16 h) were used. Once the re-
combinant ANISERP protein was obtained in its soluble
form, it was purified by glutathione-Sepharose 4B bead
affinity chromatography and eluted with 15 mM gluta-
thione, 100 mMTris-HCl pH 8, 0.1 % Triton X-100 elu-
tion buffer. The purified recombinant protein was then
dialyzed. The protein concentration was determined
using the BCA Protein Assay Kit (Thermo Scientific),
with bovine serum albumin (BSA) as a standard [22].
The expressed protein was then subjected to SDS-PAGE
analysis and Coomassie staining, plus Western blot ana-
lysis with an anti-GST antibody (GE Healthcare Life
Sciences).
Subcloning, expression in Sf9 insect cells, and purification
of recombinant His-tagged ANISERP protein. Mass
spectrometry analysis
The AniSerp gene was amplified using the oligonucleotides
AniSerp_Fw 5′ GGGGACAAGTTTGTACAAAAAAGCA
GGCTTCATGCAGCAGACAATCGATGATGCCCAAGC
3′ and AniSerp_Rv 5′ GGGGACCACTTTGTACAAGAA
AGCTGGGTTCAGTGGAAACGACCAATAAACAGA
ATGCG 3′ (Sigma Genosys). A recombinant bacmid
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Gateway Cloning System (Life Technologies), follow-
ing the manufacturer’s instructions. The bacmid DNA
(1–2 μg) was transfected into Sf9 insect cells with
Cellfectin® II Reagent (Invitrogen), following the man-
ufacturer’s instructions, yielding infectious recombin-
ant baculovirus particles. The transfected Sf9 insect
cells were cultured in TC100-Insect Medium (Sigma-
Aldrich), containing 10 % FBS (Gibco), to produce
large amounts of the recombinant ANISERP protein.
Soluble His-tagged ANISERP protein was then purified
by affinity chromatography, with a 1 ml HiTrapTM FF
crude column (GE Healthcare) and an ÅKTA FPLC system
(GE Healthcare), according to standard procedures.
Fractions were analyzed in SDS-PAGE gels stained
with Coomassie Brilliant Blue (Bio-Rad). The ANISERP
protein from different fractions was pooled, dialyzed against
PBS, quantified by the BCA method, and stored at−80 °C
until use. Finally, the identity of the recombinant protein
was confirmed by MALDI-TOF mass spectrometry, ac-
cording to standard procedures [19].
Inhibitory assays
The inhibitory activity of ANISERP against 10 protein-
ases (trypsin, chymotrypsin, plasmin, elastase, FXa, FXIa,
FXIIa, thrombin, cathepsin G and cathepsin L) was ex-
amined by measuring the residual proteolytic activity on
specific proteinase substrates after the incubation of
each enzyme with purified recombinant ANISERP.
Table 1 includes the reaction conditions for each pro-
teinase tested. In addition, and taking into account the
report by Morris and Sakanari [15], ANISERP inhib-
ition of serine proteinase activity in A. simplex crude
extract was determined using Z-Gly-Pro-Arg-AMC in
50 mMTris/HCl pH 7.5 plus 20 mMNaCl as a sub-
strate. All substrates were purchased from Sigma
Aldrich. Assays were performed after incubation of
ANISERP with each enzyme for 10 min at 37 °C in theTable 1 Enzymes, substrates and reaction conditions for each prote
Enzyme [Enzyme] [Substrate] 250 μM
Thrombin 74 nM Boc-Val-Arg -AMC
Trypsin 54 nM Boc-Gln-Ala-Arg-AMC
Cathepsin G 0.33 nM N-Succinyl-Ala-Ala-Phe-AMC.
Cathepsin L 0.83 nM Z-Phe-Arg-AMC
Plasmine 333 nM Nt-Boc-Val-Leu-Lys-AMC
Elastase 1.2 nM N-Methoxysuccinyl-Ala-Ala-Pro-Val-7
Chymotrypsin 0.012 nM N-succinyl-Lelu-Leu-Val-Tyr-7 amido
Factor Xa 0.054 nM Boc-Ile-Glu-Gly-Arg-7 amido AMC
Factor XIa 14,000 nM Boc-Phe-Ser-Arg-7 amido AMC
Factor XIIa 0.0017 nM Boc-Val-Arg-AMCappropriate reaction buffer. In all cases, the enzyme
concentrations used in the assays were linearly related
to the reaction time (30 min). The inhibition controls
used were AEBSF (1 mM) (serine-proteinases inhibitor)
and E-64 (10 μM; a cysteine proteinase inhibitor), both
obtained from Sigma-Aldrich. After addition of the
substrate (final concentration 250 μM) to the reaction
mixture, the residual enzyme activity was measured by
continuous monitoring for AMC substrates at excitation
and emission wavelengths of 380 and 460 nm respectively,
in a Victor 3 1420 Perkin Elmer Fluorescence microplate
reader (Perkin Elmer España S.L.). Reactions with the
pNA substrate were monitored, at 405 nm, in an ELX
800TM Bioteck Absorbance microplate reader (Bioteck).
Purified GST was also used as a negative control for pro-
teinase inhibition when ANISERP was produced in
pGEX4T2/E. coli.Anti-ANISERP hyperimmune sera
A female New Zealand rabbit was immunized, via sub-
cutaneous injection, with ANISERP recombinant pro-
tein fused to GST (glutathione transferase), by using
the following protocol: 75 μg/ ml of ANISERP recom-
binant protein was equally emulsified with Freund
Adjuvant and administered in three doses, a single dose
with Freund Complete Adjuvant (ACF) and the
remaining two with Freund Incomplete Adjuvant (FIA)
20 and 40 days after the first injection. Blood samples
were collected prior to the first injection and two
months after the last injection. Serum samples were
collected after centrifugation of clotted blood and
stored at−20 °C until use.Ethical approval
The rabbit was maintained and immunized in accord-
ance with institutional and national guidelines. The
protocol was approved by the Ethics Committee forinase tested
Activity buffer
50 mM Tris–HCl pH 8, 100 mM NaCl
50 mM Tris–HCl pH 8, 1 mM CaCl2, 0.15 M NaCl
50 mM HEPES/NaOH pH 7.5
Sodium acetate 100 mM pH 5.5, 1 mM EDTA, 4 mM
DTT, 0.001% BSA
50 mM Tris–HCl pH 8, 50 mM NaCl
amido AMC 25 mM Tris–HCl pH 8, 100 mM NaCl, 1 mM CaCl2
AMC 100 mM HEPES/ NaOH pH 7.5
50 mM Tris–HCl pH 8.3, 5 mM CaCl2, 0.2 mM NaCl
50 mM Tris–HCl pH 8, 100 mM NaCl, 1 mM CaCl2
4 mM Sodium Acetate-HCl/0.15 M NaCl/pH 5.3
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(CBA N# 09_2014_v2).Immunohistochemical localization of ANISERP
Live third-stage larvae of A. simplex were collected from
the body cavity of blue whiting (Micromesistiuspoutassou)
purchased at a local market, washed several times in
physiological saline, cut into two portions (of which the
anterior one-third includes the ventricle and part of the
intestine) and fixed in 10 % buffered formalin for 12 h.
After fixation, the samples were washed with PBS,
dehydrated, embedded in paraffin and cut into 5 μm-
thick sections, as previously described [23]. Once
deparaffinized and hydrated, the slides were blocked
with PBS containing 0.05 % Tween 20 and 1 % dry
skimmed milk (PBS-T-SM) for 2 h at room temperature
(RT). As ANISERP was expressed as a GST-fusion pro-
tein, and to inhibit any potential cross-reactivity with
GST from Anisakis, rabbit hyperimmune serum raised
against recombinant ANISERP and preimmune serum
(as negative control) were diluted 1/100 and preincu-
bated with or without GST, at 50 μg/ml, in PBS-T-SM
for 1 h at RT. The samples were then placed on the
slides and incubated for 2 h at RT. The slides were
washed three times with PBS-T (for 5 min each time)
and then incubated with 0.3 % hydrogen peroxide in
PBS for 30 min RT to quench endogenous peroxidase
activity. The sections were washed and incubated with
peroxidase-conjugated goat anti-rabbit IgG (Bio-Rad)
diluted 1/200 in PBS-T-SM for 1 h at RT. The slides
were washed again, and bound antibodies were revealed
with 0.5 mg/ml 4-chloro-1-naphthol (Sigma-Aldrich) in
TBS with 0.005 % hydrogen peroxide. Finally, sections
were washed with TBS and mounted with glass cover-
slips in PBS-glycerol (1:1) for examination and photog-
raphy. The slides were then stained with Wheatley’s
trichrome, as described elsewhere [24].Effect of heparin on the thrombin inhibition assay
Assays were performed with 200 μl of 50 mMTris/HCl,
100 mMNaCl, pH 8. Inhibition reaction mixtures con-
tained from 0.1 μg/ml to 100 μg/ml (0.1, 5, 15, 25, 45,
70 and 100 μg/ml) heparin and 2.7 nM ANISERP. The
reaction was initiated by adding 74 nM thrombin. After
incubation of the plates for 5 min, 50 μl of a solution
containing 250 μM Boc-Val-Arg-AMC and 0.33 mg/ml
Polybrene (Sigma-Aldrich) was added. Residual throm-
bin activity was determined by measuring the hydrolysis
of the fluorescent substrate (Boc-Val-Pro-Arg-AMC) in
a Victor 3 1420 Perkin Elmer fluorescent microplate
reader. As a positive control, the same experiment was
performed with antithrombin (AT) (0.1 mg/ml) instead
of ANISERP.Modelling procedures
Structural three-dimensional models for ANISERP were
constructed by homology modelling procedures based
on Protein Data Bank structures (selected on the basis
of strong sequence similarity, coverage and sequence-
to-structure compatibility), using both BLAST [20] and
threading (Phyre server [25]) procedures. The template
selected was 1JMO (the structure of the human heparin
cofactor II [HCII]-thrombin complex) [26]. The model
was produced using the SWISS-MODEL server facil-
ities [27–29] at http://swissmodel.expasy.org/SWISS-
MODEL.html. The structural quality of the models was
checked using the analytical programs provided by the
same server (Anolea/Gromos/Verify3D). For geometric
optimization, the models were energy minimized using
the DeepView GROMOS 43B1 force field routine [30],
by applying 500 steps of steepest descent minimization
followed by 500 steps of conjugate-gradient minimization.
The structure of human thrombin, included in PDB file
1JMO, was also re-modelled to include a serine residue at
catalytic position 205, which is an alanine in the crystal-
lized protein. Finally, in order to produce a high quality
model for the proposed contact between human thrombin
and ANISERP, the structure resulting from homology
modelling was subjected to a 2 ns standard molecular dy-
namics simulation using the PMEMD module of the
AMBER9 software package [31] and the parm99 param-
eter set for the same distribution.
To compare the 3D positions of putative heparin bind-
ing sites, structural alignment between the ANISERP
model (after molecular dynamics procedures) and the
Protein Data Bank structures of human HCII (1JMO)
[26] and human AT-III (1 ATH_A) [32]) was performed
using the Dali program [33]. Structure plots were gener-
ated using the PyMOL program (DeLano Scientific).
Results and discussion
The truncated AniSerp gene was cloned during the
screening of an A. simplex L3 cDNA library. The frag-
ment was 1005 nt long (334 aa) and lacked the 5′ end. It
showed notable similarity to serine proteinase inhibitors
(GenBank). Amplification of the 5′ end was then per-
formed by RACE-PCR with new primers based on the
truncated gene, and the full sequence was isolated in the
same way. The novel sequence contained 1194 nucleo-
tides and expressed a deduced amino acid backbone of
397 residues (with a predicted molecular weight of
44.6 kDa) plus a putative N-terminal signal peptide of 25
residues. Bioinformatic analysis showed that the gene
included a serpin signature (374–384 residues: FIADHP-
FIFTI) and a potential reactive centre loop (RCL) (p17
[E]-p16 [E/K/R]-p15 [G]-p14 [T/S]-p13 [X]-p12-9 [A/G/
S]-p8-1 [X]-p1′-4′). Database comparisons showed similar-
ities between ANISERP and different serine proteinase
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similarity scores were obtained for the serpins described in
Toxocaracanis (putative serpin-like protein [2e-141, 59 %;
KHN 72249.1]), Ascarissuum (putative serpin-like protein
[1e-103, 45 %; ERG 78895.1] and serpin b6 [3e-102, 46 %;
ERG 82472.1]). ANISERP also showed similarity to the
Bostaurus serpin peptidase inhibitor (4e-69, 38 %,
NP001193642.1), mouse (Mus musculus) serpin 3b (3e-68,
37 %, NP941373.1) and mouse squamous cell carcinoma
antigen 2-related protein 1 (2e-67, 36 %, AAN62872.1).
These findings were used together to design ANISERP
functional characterization experiments.
To obtain the recombinant ANISERP protein, the gene
without the putative N-terminal signal peptide was sub-
cloned into pGEX, and the full sequence was subcloned
into the baculovirus vector system. These genes were
expressed in prokaryotic and eukaryotic cells respect-
ively, and they were then purified. To collect the pro-
teins in functional form, different expression conditions
were tested. For the E. coli system, the conditions were
0.01 mM IPTG and incubation at 16 °C for 16 h. For the
baculovirus system, the conditions were a multiplicity of
infection of 0.1 (virus titre 5×106pfu/ml), incubation at
27 °C and collection at 72 h.
The effect of the recombinant ANISERP on proteolytic
activity was the same in both prokaryotic and eukaryoticFig. 1 Effect of ANISERP on the proteolytic activity of human thrombin, try
of recombinant ANISERP, expressed in a baculovirus system, on the enzym
(54 nM) on Boc-Gln-Ala-Arg-AMC, c Cathepsin L (0.83 nM) on Z-Phe-Arg-AMsystems. ANISERP has two potential N-glycosylation
sites, 87-NDSA and 327-NDSL, which do not appear to
influence its inhibitory effect. ANISERP inhibited throm-
bin (IC50 152 nM), trypsin (IC50 173 nM), cathepsin G
(IC50 542 nM) and cathepsin L (IC50 217 nM) in a
concentration-dependent manner (Fig. 1). No other pro-
teinase, including the parasite peptidase, was affected.
This suggests that the Anisakis peptidase described by
Morris & Sakanari [15] is not the biological target of
ANISERP. Complete inhibition of cysteine and serine
proteinases was observed when E-64 (10 μM) and
AEBSF (1 mM) were used as positive controls (data not
shown). The inhibition of cathepsin L activity confirmed
the cross-class nature of ANISERP.
To locate the possible site of synthesis and final destin-
ation of ANISERP, an immunohistochemical study was per-
formed on A. simplex L3 tissues by using a hyperimmune
serum raised against recombinant ANISERP-GST. Pre-
incubation of the serum with GST did not inhibit the
intensity of staining by immunohistochemistry or the
signal obtained by indirect ELISA against A. simplex
crude extracts (data not shown), indicating that recog-
nition was specific to ANISERP. As shown in Fig. 2a
and c, ANISERP was highly concentrated in the pseu-
docoelomic fluid (haemolymph) and in non-contractile
cell bodies (myocytons) of the somatic musculature,psin, cathepsin L and cathepsin G. Inhibitory effect of different doses
atic activity of a Thrombin (74 nM) on Boc-Val-Arg-AMC, b Trypsin
C, and d Cathepsin G (0.33 nM) on N-succinyl-Ala-Ala-Phe-AMC
Fig. 2 Immunolocalization of ANISERP in sections of Anisakis simplex
L3 with a rabbit hyperimmune serum. a Cross section at the level of
the oesophagus showing strongly positive staining in SM and PF,
moderate staining in SOM and slight staining of LC. No staining
was observed in the EC. b The negative control incubated with
the preimmune serum did not stain. c Cross section through the
intestinal level showing in detail strongly positive immunostaining
in the SM, which is restricted to the nSM; no staining was observed in
the cSM, the C or EC, including the ca. Less intense staining was also
observed in IC. d Section C was decolorized to remove the 4CN stain
and subsequently stained with Wheatley’s trichrome. DOG, dorsal
oesophageal gland; SOM, subventral muscular sectors of oesophagus;
SM, somatic musculature; LC, lateral hypodermal cords; PF,
pseudocoelomic fluid; EC, excretory cell; V, ventricle; IC, intestinal
cells; nSM, non-contractile portion of somatic muscle cells (myocytons);
cSM, contractile portion of somatic muscle cells; C, cuticle; ca, excretory
canal; n, nucleus
Table 2 Summary of the immunohistochemical staining
results indicating the tissue distribution of ANISERP
Structures Staininga Structures Staininga
Dorsal oesophageal gland - Excretory cell -
Subventral muscular sectors
of oesophagus
++ Excretory canal -
Ventricle - Hypodermis ±
Intestine ++ Lateral hypodermal
cords
±
Intestinal lumen - Cuticle -
Pseudocoelom fluid +++ Somatic muscle cell
bodies
+++
a-,no staining; ±, weak staining; +, ++ and +++, increasing intensity of
positive staining
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cells (see Fig. 2d for better identification of the struc-
tures). Positive staining was also found to a lesser
extent in cells belonging to subventral muscular sectors
of the oesophagus and intestine, and weak staining was
observed in the lateral hypodermal cords and hypoder-
mis. In addition to the contractile portion of somatic
muscle cells, other structures that did not stain
included the cuticle, the dorsal oesophageal gland, the
excretory cell (including the excretory canal), the intes-
tinal lumen and the ventricle (Fig. 2a and c, and
Table 2).
When marine mammals or humans are infected by L3
Anisakis larvae, three sources of parasite antigens can be
delivered to host tissues while larvae remain alive: i)
cuticle antigens, which are in direct contact with host
tissues, ii) gut antigens, which can be released throughthe mouth/anus, and iii) secretory antigens, which are
released by the excretory cell through the excretory
pore, located at the base of subventral lips; the latter
constitutes the main source of known Anisakis allergens.
Somatic antigens can also come into contact with host
tissues, but only in cases in which larvae die and remain
in tissues (typically in chronic infections). The absence
of staining in the dorsal oesophageal gland, intestinal
lumen, excretory cell and cuticle (Table 2) clearly indi-
cates that ANISERP is not released to the external
medium and, consequently, its inhibitory action is prob-
ably directed against endogenous proteases. This explains
why the recombinant ANISERP was not recognized by
sera from patients infected with Anisakis during the acute
phase (data not shown).
As the strongest staining was observed in myocytons
and pseudocoelomic fluid, we can hypothesize that som-
atic muscle cells are the major source of ANISERP,
which can be then released to the haemolymph.
Although the putative secretory functions of somatic
muscle cells in Anisakis have not been reported before,
this type of activity has been reported in muscular cells
of Caenorhabditis elegans transfected with a plasmid
encoding a signal peptide fused to green fluorescent protein
[34]. The presence of a putative signal peptide in ANISERP
is consistent with this hypothesis.
In addition to myocytons and pseudocoelomic fluid,
staining for ANISERP was also intense in intestinal cells.
As intestinal and muscular cells originate from different
germinal layers (i.e. endoderm and mesoderm respect-
ively), we can also hypothesize that more than one Ani-
sakis serpin is recognized by the polyclonal antibody.
Although this possibility merits further investigation, the
fact that other similar serpins exist in the Anisakis tran-
scriptome (unpublished results) is consistent with the
hypothesis.
Finally, an in silico analysis of the ANISERP molecule
was performed to predict its tertiary structure and help
to determine how it might interact with the serin
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conserved serpin folding. Thrombin protease was chosen
as a model as it yielded the lowest IC50. To obtain a reli-
able representation of the actual interactions between
proteins, a homology-based 3D model of ANISERP
bound to thrombin was generated. To obtain an even
more realistic molecular model for the Anisakis serpin,
the Ala205 located at the catalytic centre of human
thrombin was substituted by a Ser residue (model
1JMO). On the basis of the initial interaction model,
short-step (2 ns) molecular dynamics were applied to
the whole structure to help the amino acid side chains
and the reactive centre loop (RCL) backbone achieve a
stable, low-energy conformation that would allow ana-
lysis of specific contacts between the two proteins
(Fig. 3a). The ANISERP model showed all the character-
istics described for classic mammalian serpins, i.e. mixed
parallel and antiparallel six-stranded β-sheets with the
central strand containing several residues from the RCL.
This observation is consistent with that reported by
Zang & Maizels [35], i.e. although overall nematode ser-
pins show less primary sequence similarity to their
mammalian homologues, they can acquire a common,
highly ordered tertiary structure. Figure 3b shows the
thrombin substrate groove involving ANISERP aminoA
Fig. 3 Model for ANISERP-human thrombin binding. a General view of the
ANISERP reactive centre loop (RCL [green]) in the structural groove of the t
theoretical electrostatic properties (blue = positive, red= negative). b Residues in t
Phe374 in ANISERP. c Position of residues in the catalytic triad of human
ANISERP residues Arg361 and Ser362 (P1 and P1′ respectively). Distances betw
compatible with proteinase activity, are indicatedacids from Met358 to Phe374. Contacts between resi-
dues of the two proteins in this region involve hydro-
phobic clusters and the junctions at the active centre,
including contact between the thrombin catalytic triad
His43, Asp99 and Ser205 and the ANISERP Arg361 (P1)
and Ser362 (P1′) residues (Fig. 3c).
In the human coagulation cascade, AT III inhibits the
serine proteinases trypsin and plasmin along with the
coagulation factors thrombin and FXa. The effect of
ANISERP on FXa was therefore tested. No inhibition
was observed, as indicated above (data not shown). In
contrast, HCII inhibits the serine proteases thrombin,
chymotrypsin and cathepsin G. The distinct enzyme
specificities of ATand HCII appear to be the result of
amino acid changes in P1 and the immediately adja-
cent residues of the RCL-enzyme recognition sequence.
AT, which has an Arg at P1, is an inhibitor of the Arg-
proteinases thrombin and FXa, while HCII is a specific
thrombin inhibitor with an unfavourable Leu residue at P1
[36]. The inhibitory activity of ANISERP, which selectively
blocks human thrombin without affecting FXa, may be
explained by considering that it has an Arg at P1, as does
AT. In addition, the 14 amino acid changes in the adjacent
residues of the RCL may be responsible for the different
specificities of ANISERP, including the lack of FXa activity.B
C
model for ANISERP binding to human thrombin. The location of the
hrombin is indicated. The thrombin surface is coloured according to its
he heavy chain of human thrombin; binding of amino acids Met358 and
thrombin (His43, Asp99 and Ser205) and their positions relative to
een active residues and atoms in the peptide bond of the substrate,
Fig. 4 Effect of heparin on ANISERP inhibition of human thrombin proteolytic activity. Residual activity of thrombin after incubation with
recombinant ANISERP (circles) or AT (squares) with increasing concentrations of heparin (0.1-100 μg/ ml). ANISERP was used at a fixed
concentration of 2.17 nM (IC50: 152 nM)
Fig. 5 Sequence and structural alignment of ANISERP, human antithrombin III (1 ATH_A), and human heparin cofactor-II (1JMO). The key residues
involved in heparin binding described for human antithrombin III (Arg 47, Lys114, Lys125, Arg 129, Arg132 and Lys133) are shown as purple boxes
and spheres. The key residues involved in heparin binding described for heparin cofactor-II (Lys173, Arg184, Lys185, Arg189, Arg192 and Arg193)
are shown as blue spheres. The positions of the P1-P1’residues in the ANISERP sequence are indicated. The residues in the 1JMO and 1ATH_A
sequences are numbered according to Baglin et al. [26]
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structed by site-directed mutagenesis should be conducted
to assess whether these changes in the RCL are involved in
the specific reaction between ANISERP and thrombin.
As there is some evidence [37, 38] that the activity of the
AT and HCII inhibitors is greatly potentiated by heparin,
the effect of heparin on ANISERP inhibitory activity on
thrombin was also studied. Heparin (0.1 to 100 μg/ml) did
not affect the ANISERP inhibitory activity, although it did
increase the inhibitory activity of the AT control in a
concentration-dependent manner (Fig. 4).
In an attempt to understand the lack of effect of hep-
arin on the ANISERP anticoagulant action, the hypo-
thetical heparin binding site residues were aligned with
the AT and HCII heparin binding site residues described
elsewhere [26]. Figure 5 shows the sequence and structural
alignments of the three proteins. Five residues (Lys173,
Arg184, Lys185, Arg189, and Arg192 blue spheres in Fig. 5)
out of six critical for HCII/heparin binding appear to be
absent/altered in ANISERP.
Conclusions
ANISERP is an internally-secreted Anisakis serpin that
displays in vitro inhibitory activity. The inhibitory action
of ANISERP against thrombin appears to depend on a
suicide substrate-like inhibitory mechanism, similar to
that displayed by human AT-III. The fact that heparin
does not modulate the anticoagulant activity of ANI-
SERP might be explained by the absence in its structure
of five of the six positively charged residues usually seen
in the AT-III-heparin binding site. The findings of the
immunolocalization study indicate that ANISERP exerts
its function as an internal regulatory serpin and rule out
a role at the parasite-host interface.
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